2026-2034年牛暂缓发热疫苗全球市场规模、份额、趋势和成长分析报告

预计牛传染性发烧疫苗市场规模将从 2025 年的 8,274 万美元成长到 2034 年的 1.1494 亿美元，2026 年至 2034 年的复合年增长率为 3.72%。

由于牛疾病发生率不断上升以及人们对动物健康管理的意识提升，牛暂时性发烧（TSF）疫苗的全球市场正蓬勃发展。 TSF（俗称三日热）对牛的生产力影响巨大，导致酪农和畜牧业遭受经济损失。对优质动物性蛋白质需求的增长以及畜群管理实践的改进正在推动全球疫苗的普及应用。

政府主导的牲畜疫苗接种计划和兽医学的进步是市场的主要驱动力。在酪农产业不断发展的开发中国家，为确保稳定生产，对动物预防保健的投资正在增加。人们对粮食安全和永续畜牧业日益增长的关注进一步推动了疫苗接种计划的发展。製药公司正在投资研发改良的疫苗配方，以提高疫苗效力并延长免疫持续时间。

预计未来成长将主要得益于畜牧业商业化进程的推进和数位化动物健康监测系统的整合。气候变迁和媒介传播疾病的蔓延可能会凸显预防性疫苗接种策略的重要性。加强分销网络将透过扩大兽医基础设施和强化公私合营来实现。随着全球对安全、优质动物产品的需求持续成长，市场可望保持稳定成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球牛暂症发热疫苗市场：依疫苗类型划分

• 市场分析、洞察与预测
• 活病毒疫苗
• 灭活疫苗
• 其他的

第五章 全球牛暂缓发热疫苗市场：依应用划分

• 市场分析、洞察与预测
• 牛
• 水牛

第六章 全球牛暂缓发热疫苗市场：依最终用户划分

• 市场分析、洞察与预测
• 医疗设备製造商
• 製药业
• 动物医院
• 其他最终用户

第七章 全球牛暂缓发热疫苗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 亚太其他地区
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Zoetis Services LLC
  • Nutri Pharmax Sdn Bhd
  • Octavoscene（Pty）Ltd
  • Kyoto Biken Laboratories Inc
  • Indian Immunologicals Ltd
  • CAVAC Network
  • Onderstepoort Biological Products SOC Ltd
  • Green Cross Veterinary Products Co. Ltd
  • Veterinary Serum & Vaccine Research Institute
  • Boehringer Ingelheim International GmbH

The Bovine Ephemeral Fever Vaccines Market size is expected to reach USD 114.94 Million in 2034 from USD 82.74 Million (2025) growing at a CAGR of 3.72% during 2026-2034.

The Global Bovine Ephemeral Fever Vaccines Market is gaining momentum due to increasing livestock disease outbreaks and rising awareness about animal health management. Bovine ephemeral fever, commonly known as three-day sickness, significantly impacts cattle productivity, leading to economic losses in dairy and meat industries. Growing demand for quality animal protein and improved herd management practices are driving vaccination adoption worldwide.

Government-led livestock immunization programs and veterinary healthcare advancements are key market drivers. Developing countries with expanding dairy sectors are increasingly investing in preventive animal healthcare to ensure stable production. Rising focus on food security and sustainable livestock farming is further encouraging vaccination programs. Pharmaceutical companies are investing in improved vaccine formulations with enhanced efficacy and longer immunity duration.

Future growth is expected to be supported by increasing commercialization of livestock farming and the integration of digital animal health monitoring systems. Climate change and vector-borne disease spread may elevate the importance of preventive vaccination strategies. Expanding veterinary infrastructure and public-private partnerships will strengthen distribution networks. The market is poised for steady growth as global demand for safe and high-quality animal products continues to rise.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Vaccine Type

• Live Vaccine
• Killed Vaccine
• Others

By Application

• Cattle
• Water Buffaloes

By End Users

• Medical Device Companies
• Pharmaceutical Industries
• Animal Hospitals
• Other End Users

COMPANIES PROFILED

• Zoetis Services LLC, Nutri Pharmax Sdn Bhd, Octavoscene Pty Ltd, Kyoto Biken Laboratories Inc, Indian Immunologicals Ltd, CAVAC Network, Onderstepoort Biological Products SOC Ltd, Green Cross Veterinary Products Co Ltd, Veterinary Serum Vaccine Research Institute, Boehringer Ingelheim International GmbH
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET: BY VACCINE TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Vaccine Type
• 4.2. Live Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Killed Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET: BY APPLICATION 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Cattle Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Water Buffaloes Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET: BY END USERS 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast End Users
• 6.2. Medical Device Companies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Pharmaceutical Industries Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Animal Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.5. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET: BY REGION 2022-2034(USD MN and Million Doses)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.2.1 By Vaccine Type
  • 7.2.2 By Application
  • 7.2.3 By End Users
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.3.1 By Vaccine Type
  • 7.3.2 By Application
  • 7.3.3 By End Users
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.4.1 By Vaccine Type
  • 7.4.2 By Application
  • 7.4.3 By End Users
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.5.1 By Vaccine Type
  • 7.5.2 By Application
  • 7.5.3 By End Users
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.6.1 By Vaccine Type
  • 7.6.2 By Application
  • 7.6.3 By End Users
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL BOVINE EPHEMERAL FEVER VACCINES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Zoetis Services LLC
  • 9.2.2 Nutri Pharmax Sdn Bhd
  • 9.2.3 Octavoscene (Pty) Ltd
  • 9.2.4 Kyoto Biken Laboratories Inc
  • 9.2.5 Indian Immunologicals Ltd
  • 9.2.6 CAVAC Network
  • 9.2.7 Onderstepoort Biological Products SOC Ltd
  • 9.2.8 Green Cross Veterinary Products Co. Ltd
  • 9.2.9 Veterinary Serum & Vaccine Research Institute
  • 9.2.10 Boehringer Ingelheim International GmbH